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Abstract
Objective: To assess the effects of an antiseptic, non-alcohol based mouth-rinse containing chlorhexidine and 
cetylpyridinium chloride, in preventing the oral complications associated to radiation therapy in head-and-neck 
cancer patients.
Study design: This was a parallel, double blind, prospective, randomized clinical trial. Cancer patients were ran-
domly assigned to one of the two treatments (test mouth-rinse or a placebo). Three visits were scheduled (baseline, 
14 and 28 days). Different outcome variables were evaluated: mucositis, plaque and gingival indices, stimulated 
saliva and salivary pH.
Results: 70 patients were screened and 36 were included. The presence and the degree of mucositis significantly 
increased in both groups and no significant differences were detected between groups, although the median in-
crease in the placebo group (1.81) at 2 weeks was higher than in the test group (1.20). 
Conclusions: Within the limitations of the small sample size, this study suggests that the use of the tested mouth-
rinse may lead to some improvements in clinical parameters in patients irradiated for head-and-neck cancer.
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Introduction
Every year, approximately 1.3 millions of Europeans are 
diagnosed of cancer and more than 0.8 millions die of 
this disease. In Spain, cancer is the main cause of death 
(90.000 cancer patients per year, 25% of all deaths), ac-
cording to the information provided by the Ministry of 
Health in 2006. Oral cancer represents 2-4% of all di-
agnosed cancers in Spain, and its prevalence ranges be-
tween 11.4-17.4% per 100 000 inhabitants. Among the 
intraoral locations, the tongue (25.1%) and the floor of 
the mouth (10.2%) are the most common. 
Treatment for oral cancer (either radiotherapy and/or 
chemotherapy) is becoming increasingly effective, but 
it is associated with both short and long-term second-
ary side effects. Among these, the most frequent is oral 
mucositis (OM) (1). 
Radio-induced OM develops in almost all patients treat-
ed for cancers in the mouth, oropharynx or nasophar-
ynx, and in two thirds of the cancers in the larynx or 
hypopharynx (2,3). The risk of OM and its severity is 
related to the characteristics of the radiation therapy, 
such as dose, field size and fractionation, as well as to 
the patient’s oral hygiene during therapy. Hyper-frac-
tionation and combination with chemotherapy increase 
the prevalence, severity and duration of OM (2,4).
Radio-induced OM affects mainly non-queratinized 
oral mucosa, such as lip and buccal mucosae, lateral and 
anterior mucosae of the tongue, floor of the mouth , and, 
less frequently, hard palate mucosa (2,4). Early signs of 
OM include erythema that appears after approximately 
10 Gy of cumulative radiation dosage for head and neck 
(H&N) (4). After 7-10 days, or a cumulative dosage of 
30 Gy, ulcers are detected, associated to discomfort and 
changes in patient dietary habits (2,4). Radio-induced 
OM lasts for at least 2 weeks after radiation therapy 
have finished (2,4). The impact of OM can be very im-
portant, since patients may need hospitalization or even 
modifications in their cancer therapy (1-4 ,5).  
Stokman and coworkers (2), in a meta-analysis of 45 
studies and 8 interventions, concluded that “to date, no 
single intervention completely prevents oral mucositis”. 
However, they identified treatments with significant 
preventive effect, such as PTA (combination of the an-
timicrobials polymyxin E, tobramycine and ampho-
tericin B), GM-CSF (granolocyte-macrophage colony-
stimulating factor), oral cooling by means of ice chips, 
and amifostine. More recently, two systematic reviews 
on preventive (6) (including 89 studies and 29 interven-
tions) and on therapeutic approaches (7) (with 26 stud-
ies) concluded that some benefit could be obtain with 
certain strategies, such as: amifostine, natural remedies 
from chinese medicine and hydrolytic enzymes, espe-
cially in the prevention and the reduction of its severity. 
It has been suggested, therefore, that the best approach 
may be the use of a combined preventive therapy strat-
egy. Following this concept, protocols of oral care for 
patients in radiotherapy for H&N tumours have devel-
oped, including the use of soft tooth brushes, periodic 
oral health assessments and follow up and the inclusion 
of dentists in the multidisciplinary team (8).
The mouth of patients under radiotherapy for H&N 
cancer should be carefully supervised, even before the 
initiation of the therapy, with the goal of achieving low 
plaque and gingivitis levels. During therapy, when me-
chanical plaque control might be difficult or inadequate, 
chemical plaque control may be beneficial. Among the 
agents used in chemical plaque control, chlorhexidine 
(CHX) is the most active, due to its wide spectrum (in-
cluding yeasts) and high substantivity. Its safety has 
been proved in long-term studies, although the occur-
rence of side effects is frequent, including tooth stain-
ing and soft tissue and taste alterations. Studies with 
CHX have demonstrated its capacity to prevent oral 
complications, such as the occurrence of chronic or 
opportunistic infections, including Candida sp. Infec-
tions, in high risk patients (irradiated patients, patients 
in chemotherapy or bone marrow transplant recipients) 
(for review, see (9)). 
Usage of CHX mouth rinses may reduce the bacteri-
al and fungal colonization in the mouth (9), and since 
gram-negative anaerobic bacterial species may have a 
role in the pathogenesis of OM (10), CHX thus may help 
to prevent or decrease the severity of OM. Some studies 
with different designs have already tested the hypoth-
esis (11-15) with variable results that make not possible 
to confirm or reject the hypothesis (6).
In the last years, new CHX formulations have been 
marketed, with the goal of reducing secondary effects 
(e.g. by excluding alcohol from the formulation), or in-
creasing its antimicrobial effect (e.g. by adding other 
active agents). Among these new formulations, a mouth 
rinse that combines CHX with cetyl-pyridinium chlo-
ride (CPC), and no alcohol, has been tested (16), dem-
onstrating an increase in antibacterial activity. Due to 
the lack of alcohol and to the increased antimicrobial 
activity, we hypothesized that the use of this specific 
mouth rinse may be beneficial for the oral health status 
in irradiated patients for H&N cancer.
Thus, the aim of this randomised clinical trial was to 
assess the effects of an antiseptic mouth rinse, with 
CHX and CPC and no alcohol, in the prevention of oral 
complications associated to irradiation in H&N cancer 
patients.
Patients and Methods
Patients
Consecutive patients were selected at the Oncology 
Radiotherapy Service at the “12 de Octubre” Hospital 
(Madrid), using the following criteria: 
Inclusion criteria: irradiated as part of the therapy of 
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head-and-neck cancer; aged 18-75; at least 10 teeth; in-
formed consent.
Exclusion criteria: patients already diagnosed of suf-
fering a mucosal pathology, such as lichen or lupus; 
pregnant women; patients with orthodontic therapy.
Methods
Study design
The study was a parallel, double-blind, prospective, 
randomised clinical trial.
Patients were screened for compliance with the inclu-
sion and exclusion criteria and once they agreed to par-
ticipate by signing the IRB approved informed consent; 
they were entered in the study and appointed for the 
baseline visit.
The study consisted on three visits:
• Visit 1 or baseline: the day when radio-therapy was 
started.
• Visit 2: 14 days after baseline.
• Visit 3 or final visit: 28 days after baseline.
- Visit 1. Baseline.
Patients were examined, outcome variables were re-
corded and samples for microbiology were collected. 
The following outcome variables were recorded: degree 
of mucositis, plaque and gingival indices, presence of 
caries and amounts and pH of saliva.
After this evaluation, all participating patients were ran-
domised and the treatments were allocated by providing 
the assigned mouth rinse together with the instructions 
for use. They were then appointed for the next visit ac-
cording to the study plan.
-Visit 2. 14-day evaluation.
The same sampling and registration of outcome vari-
ables were done again, together with an interview with 
the patient assessing their compliance in using the as-
signed mouth rinse and the occurrence of any adverse 
event. 
- Visit 3. Final visit after 28 days.
Identical to visit 2, the sampling, registration of out-
come variables, compliance and occurrence of any ad-
verse event were carried out.
All the outcome variables were assessment by a single 
and calibrated examiner, who was blind to the treatment 
assignment. 
Outcome variables
Evaluation of Mucositis. The Scale of the Radiation 
Therapy Oncology Group/European Organization Re-
search and Treatment of Cancer (RTOG/EORTC) was 
utilized. This scale assesses the presence of mucositis in 
different degrees based on the intensity of the affecta-
tion, from no lesion (0) to the occurrence of ulceration 
and/or necrosis (4). 
The following criteria categorize this scale from 0 – 4:
0. No lesion.
1. Eritema; may experience mild pain not requiring an-
algesic.
2. Patchy mucositis that may produce an inflammatory 
sero-sanguinitis discharge; it may experience moderate 
pain.
3. Confluent fibrinous mucositis; may include severe 
pain requiring narcotics
4. Ulceration, haemorrhage, or necrosis.
Plaque index
The index proposed by O’Leary and coworkers on 1972 
was selected: four surfaces were evaluated per tooth in 
all teeth. The number of positive surfaces were multi-
plied for 100, and divided by the total number of sur-
faces evaluated (IP= plaque positive surfaces / total 
surfaces).
Gingival index
The index proposed by Ainamo and Bay in 1975 was 
selected, and it was assessed in four surfaces per tooth 
in all teeth, as present or absent. 
Amount of stimulated saliva (mL)
Sampling of saliva was done through the “expectoration 
technique”. The patients were provided with paraffin 
that was chewed during 5 minutes. Then they are asked 
to spit all produced saliva in a graduated tube and the 
rate of salivary flow is calculated, in mL per minute. 
Salivary pH
A small amount of the saliva was collected by means 
of a pipette and a drop was placed in the yellow part 
of the Dentobuff Strip® (Orion Diagnostica, Finland), 
and let to dry for 5 min. Then, the change in colour was 
evaluated and registered and the salivary pH was calcu-
lated. The yellow colour (low buffer capacity, pH of 4 
or lower) was coded as 1, green colour (moderate buffer 
capacity, pH between 4.5 and 5.5) as 2, and the blue col-
our (high buffer capacity, pH 6 or higher) as 3.
Treatments
Patients included in the study were randomly assigned 
to one of the two treatments, either test or control. Ran-
domisation was done through a computer-generated list 
that assigned treatments by numbers. Patients received 
a number after inclusion, corresponding to a numeri-
cally coded mouth rinse. The list and the numbered bot-
tles were provided by the promoter, and the assignation 
of numbers was made by the researchers in consecutive 
order. Codes were not opened until the end of the study. 
Both patients and researchers were blinded throughout 
the study.
Patients in the test group rinsed with Perio-Aid Tratami-
ento® (Dentaid, Cerdanyola del Valles, Spain) com-
posed of 0.12% CHX and 0.05% CPC as active ingredi-
ents. Patients in the control group rinsed with a placebo 
mouth rinse, identical to the test product but without the 
active components. Both formulations lacked any alco-
hol. 
All patients received written instructions on the use 
 of their assigned treatment. In brief, they should carry 
out their usual tooth-brushing and oral hygiene proce-
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Table 1. Changes in clinical outcome variables: degree of mucositis, plaque index and gingival index.
* Negative values mean decrease. ^ Inter group comparison. sd, standard deviation.In Bold, statistically significant differences.
Clinical variables 
placebo test 
baseline-
2weeks 
baseline-
4weeks 
2weeks-
4weeks 
baseline-
2weeks 
baseline-
4weeks 
2weeks-
4weeks 
Degree of 
mucositis
n evaluated 16 12 12 15 14 14 
no change 7 2 4 7 5 10 
increase 9 9 5 8 9 4 
decrease 0 1 3 0 0 0 
median    1,5 2 0 1 1 0 
Plaque 
index * 
n evaluated 12 9 9 12 13 12 
mean -0,44 -0,70 -0,26 -0,59 -0,56 -0,05 
sd 0,61 0,94 0,65 0,89 0,81 0,30 
p value 
Wilcoxon 0.0269 0.0547 0.1484 0.0137 0.0081 0.5693 
p value 
MannWhitney^ > 0.9999 0.6642 0.4773  
Gingival
index * 
n evaluated 12 9 9 12 12 12 
mean -0,26 -0,63 -0,37 -0,14 -0,17 -0,03 
sd 0,46 0,68 0,39 0,42 0,36 0,29 
p value 
Wilcoxon 0.0322 0.0273 0.0234 0.4238 0.1230 0.8984 
p value 
MannWhitney^ 0.4023 0.0880 0.0427  
dures, and then they should rinse with 15 mL of the as-
signed product, for 30 second, twice a day (morning and 
evening). 
Statistical analyses
The study primary outcome was the occurrence and the 
changes in the degree of mucositis according to the de-
scribed scale. These changes were evaluated by means 
of the chi-square test with the Yates s´ correction. Com-
parisons between groups were assessed by means of the 
Mann-Whitney test. 
As secondary outcome variables, plaque and gingival 
indices were evaluated inter- (both at each visit and 
in changes between visit) and intra-group. Intergroup 
changes were compared by means of the Mann-Whit-
ney test, while intra-group changes were studied with 
the Wilcoxon test.
The changes in the amount of saliva in mL were as-
sessed by the t-test. The salivary pH was evaluated in 
an identical manner. 
Results
Demographic data 
A total of 70 consecutive patients were screened for in-
clusion, from May 2004 to May 2007. Finally, 36 pa-
tients (32 male and 4 female patients) were included. All 
suffered from head-and-neck carcinoma (most of them 
squamous cells carcinomas), and their oncology therapy 
included radiation in doses ranging from 50-80 Gy, de-
livered in 5 periods. From this population at baseline (18 
in the placebo group-mean age 54.3±16.1, 17 males, 6 
smokers- and 18 in the test group-mean age 49.4±15.4, 15 
males, 3 smokers), 31 patients (16 in the placebo and 15 
in the test group) completed the 2-week visit and 26 the 
4-week visit (12 in the placebo and 14 in the test group).
Reasons for drop-outs were: one patient in the placebo 
group died, one patient in the test group needed sur-
gery and another had to be admitted at the Hospital. The 
rest of the drop-outs were related to the difficulties for 
patients to comply with the appointments due to their 
health-related problems.
Clinical outcome variables (Table 1)
Out of the two patients with mucositis at baseline in the 
placebo group, one showed degree 1 and the other de-
gree 4. The 5 positive patients in the test group showed 
degrees 1, 2, 3 (2 patients) and 4, respectively. After 2 
weeks, 9 placebo patients experienced an increase in 
the degree of mucositis, and no changed was observed 
in 7 patients, with a median change of 1.5 score points. 
Med Oral Patol Oral Cir Bucal. 2010 Sep 1;15 (5):e732-8.                                                                                                                                                                   Mucositis in irradiated patients
e736
Table 2. Changes in salivary outcome variables: referred hiposialosis, stimulated saliva and salivary pH.
* Negative values mean decrease. ^ Inter group comparison. sd, standard deviation. In Bold, statistically significant 
differences.
Salivary outcome variables 
placebo test 
baseline-
2weeks 
baseline-
4weeks 
2weeks-
4weeks 
baseline-
2weeks 
baseline-
4weeks 
2weeks-
4weeks 
Changes in 
referred 
hiposialosis
evaluated 15 10 10 14 14 14 
no change  9  7 10  9  8 13 
increase  6  3  0  5  6  1 
decrease  0  0  0  0  0  0 
median  0  0  0  0  0  0 
p value 
chi-square^  1 0,8307  1  
      
Changes in 
stimulated
saliva in mL 
 * 
evaluated 9 9 8 8 7 9 
mean -2,20 -1,93 0,11 -2,19 -5,00 -1,89 
max 0,1 0,5 1 4 -0,5 0 
min -9 -8 -1,5 -11 -14 -5 
sd 3,17 3,29 0,90 4,33 4,79 1,88 
p-value
t -test 0,07 0,11 0,73 0,26 0,03 0,02 
p value 
t-test^ 0,99 0,18 0,02  
      
Changes in 
salivary pH
evaluated 9 8 8 9 7 8 
n(-2) 1 3 1 2 2 0 
n(-1) 4 3 2 2 2 0 
n(0) 4 2 4 5 3 8 
n(+1) 0 0 1 0 0 0 
p value 
chi-square 0,22 0,69 0,44 0,46 0,71 0,003 
p value 
chi-square^ 0,57 0,76 0,15  
In the test group, 8 patients suffered an increase and 
7 no change, being the median 1. The statistical com-
parison showed no significant differences between the 
medians of the groups (p=0.381), although higher mean 
values were observed in the placebo group (1.81 versus 
1.20). After 4 weeks, 9 placebo patients demonstrated 
an increment from baseline, two remained unchanged 
and one showed a decrease. The median of the increase 
was 2 score points. In the test group, 9 showed increase 
and 5 no change, being the median change of 1. No sig-
nificant differences were detected (p=0.772). The mean 
change was similar (1.75 versus 1.71).  In regards to the 
changes between 2 and 4 weeks, in the placebo group, 5 
patients increased, 3 decreased and 4 did not change. In 
the test group, no changes were detected for 10 patients 
and 4 experienced an increase. The median change was 
0, while the mean was higher for test patients (0.64) 
than for placebo patients (0.25). No significant differ-
ences were detected (p=0.779).
Plaque levels were significantly reduced in both groups 
after 2 weeks (p<0.05) and after 4 weeks (p≤0.05). 
When test and placebo groups were compared, differ-
ences were not statistically significant either at each 
study visit or in the changes between visits.
Gingivitis levels were reduced in both groups, but only 
reached the level of statistical significance in the control 
group (p<0.05). Differences between groups were sta-
tistical significant in the additional reduction between 2 
and 4 weeks, corresponding to higher reduction in the 
control group.
Salivary outcome variables (Table 2)
Stimulated salivary flow was reduced in both groups 
from baseline to 2 weeks, although not reaching the 
level of significance. From 2 to 4 weeks, patients in the 
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test group showed an additional significant (p=0.02) de-
crease. Differences between baseline and 4 weeks were 
also significant in this group (p=0.03). When both groups 
were compared, the differences in the changes between 
2 -4 weeks were statistically significant (p=0.02).
Four patients in the placebo group and 7 patients in the 
test group referred hyposialosis at baseline. No signifi-
cant differences were detected at baseline, 2 weeks or 4 
weeks. Approximately one third of the patients in both 
groups (6 in control group, and 5 in the test group) re-
ported an increase in hyposialia between baseline and 2 
weeks, after the irradiation treatment started. No addi-
tional changes were detected from 2 to 4 weeks, except 
for one patient in the test group.  No significant differ-
ences were detected between groups at each visit or in 
the changes between visits, although a higher level of 
hyposialosis was observed in test patients at baseline.
With regards to salivary pH, the buffer capacity of saliva 
decreased from baseline to 2 weeks in both groups. An 
additional decrease was observed for the control group 
from 2 to 4 weeks, while no changes were found in the 
test group. Differences between groups in the changes 2 
weeks-4 weeks, were statistically significant (p=0.003). 
However, it should be noted that the situation at baseline 
was also different, although not statistically significant, 
with a worse condition in the test group.
Adverse effects
No relevant adverse effects were reported in any group.
Discussion
The results of the present study have shown some ben-
efits in using a non-alcohol, CHX and CPC mouth rinse 
in patients undergoing radiation therapy as part of the 
treatment of a head-and-neck cancer. These results, 
however, should be interpreted with caution, due to the 
heterogeneity of the patient sample and the inherent dif-
ficulties when enrolling patients with severe health con-
ditions in clinical trials.
There are many confounding factors that may have in-
fluenced the results, such as:
- The total radiation dose and treatment regimen. In 
most patients it ranged between 50-70 Gy, fractioned in 
5 weekly sessions of 2 Gy/session, aiming at reducing 
the secondary effects and at facilitating the oxygenation 
of the tumoral cells. Since radiation damage is anatomi-
cally site-specific, its toxicity is localized to the irra-
diated tissue volumes. The degree of damage will be 
dependent on factors related to the treatment regimen, 
such as the type of radiation used, the total administered 
dose, and the field size in relation to the fractionation. 
Even for HNT, the radiation will depend on the loca-
tion and extension of the tumour, with important dif-
ferences for a T1 N0 M0 as compared with a T3 N2 M0 
of tongue, or between a cancer of cavum and a tongue 
base carcinoma.
- The tumour type, clinical stage, histology, location, 
extension...  and the existence of previous or concomi-
tant chemotherapy also provides a high degree of het-
erogeneity in the patient sample.
- The patient systemic status usually deteriorated dur-
ing the oncology therapy. The ensuing secondary ef-
fects, such as mucositis were associated with pain, 
haemorrhage and infection, which precluded a normal 
diet and an adequate oral hygiene. Even the incidence of 
candidiasis in a neutropenic patient may lead to hospi-
talization and to the temporary suspension of the radio-
therapy. These problems precluded some patients from 
continuing the study and therefore, to comply with the 
programmed study visits.
- Concomitant oral care, since patients were using, as 
part of the hospital protocols, other mouth rinses (0.1% 
hexetidine with and without alcohol,…) with different 
active ingredients that may not be considered as very 
active, but could have influenced the results.
- Patient habits, such as oral hygiene habits, alcohol con-
sumption, smoking habits...
CHX mouth rinses in the prevention of oral mucositis 
have been evaluated in at least 9 randomized clinical 
trials (2, 11-14, 17-20), but the outcomes were quite dif-
ferent. From these studies, 7 were included in a meta-
analysis (2), that showed no effect of chlorhexidine in 
the prevention of mucositis in chemotherapy and radio-
therapy patients (odds ratio 0.7; 95% confidence interval 
0.43-1.12). 
Out of these 7 studies, three evaluated the effect of CHX 
in patients under radiotherapy. In one of them (12), 30 
patients receiving high-dose head-and-neck radiation 
therapy were evaluated. A 0.12% CHX digluconate 
mouth rinse was evaluated (15 mL, 3 times a day) and 
no differences were observed in oral mucositis (“pres-
ence of mucositis” in categories ranging 0-4) between 
the control and CHX groups, although reductions in oral 
microflora were observed in the CHX group. Another 
study (13) suggested that a CHX mouthwash was detri-
mental in the management of mucositis. Finally, in the 
third study (15,19), a 0.1% CHX mouthrinse was evalu-
ated, and 30 HNT patients were included, who rinsed 
four times per day with the assigned product.  No dif-
ferences were observed between the two study groups 
in the development and severity of mucositis.
The results of this clinical investigation, however, sug-
gest clinical benefits in the use of the provided antisep-
tic oral rinse. One of the explanations for these positive 
results may be related to the improved formulation of 
the tested product that has shown higher activity (16). 
The potential benefit of the prophylactic rinse with the 
tested product, rather than on a direct effect upon oral 
mucositis, may be through the control of oral micro-
organisms together with the reduction in the occurrence 
of oropharyngeal candidosis. In addition, it is important 
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to provide these patients with supplementary supportive 
measures including dietary recommendations, such as 
strong emphasis on maintaining the nutrition and the 
use of a soft diet and the avoidance of irritants such to-
bacco, alcohol or spices. It should be pointed out that the 
results of the present study should be interpreted with 
caution, due to all the limiting factors previously enu-
merated and the reduced sample size.
Conclusions
We can conclude that, within the limitations of the small 
sample size, this study suggests that the use of a 0.12% 
CHX and 0.05% CPC mouth rinse may lead to some im-
provements in clinical parameters in patients irradiated 
for head-and-neck cancer. 
References
1. Caribé-Gomes F, Chimenos-Küstner E, López-López J, Finestres-
Zubeldia F, Guix-Melcior B. Dental management of the complications 
of radio and chemotherapy in oral cancer. Med Oral. 2003;8:178-87. 
2. Stokman MA, Spijkervet FK, Boezen HM, Schouten JP, Rooden-
burg JL, de Vries EG. Preventive intervention possibilities in radio-
therapy- and chemotherapy-induced oral mucositis: results of meta-
analyses. J Dent Res. 2006;85:690-700. 
3. Puyalt Casado M, Jiménez Martinez C, Chimenos Küstner E, 
López López J, Juliá A. A protocol for the evaluation and treatment 
of oral mucositis in patients with hematological malignancies. Med 
Oral. 2003;8:10-8. 
4. Scully C, Sonis S, Diz PD. Oral mucositis. Oral Dis. 2006;12:229-
41. 
5. Stokman MA, Spijkervet FK, Burlage FR, Dijkstra PU, Manson 
WL, de Vries EG, et al. Oral mucositis and selective elimination of 
oral flora in head and neck cancer patients receiving radiotherapy: a 
double-blind randomised clinical trial. Br J Cancer. 2003;88:1012-6. 
6. Worthington HV, Clarkson JE, Eden OB. Interventions for pre-
venting oral mucositis for patients with cancer receiving treatment. 
Cochrane Database Syst Rev. 2007;4:CD000978. 
7. Clarkson JE, Worthington HV, Eden OB. Interventions for treat-
ing oral mucositis for patients with cancer receiving treatment. Co-
chrane Database Syst Rev. 2007;2:CD001973. 
8. Keefe DM, Schubert MM, Elting LS, Sonis ST, Epstein JB, Raber-
Durlacher JE, et al. Updated clinical practice guidelines for the pre-
vention and treatment of mucositis. Cancer. 2007;109:820-31. 
9. Addy M, Moran JM. Clinical indications for the use of chemical 
adjuncts to plaque control: chlorhexidine formulations. Periodontol 
2000. 1997;15:52-4. 
10. Wijers OB, Levendag PC, Harms ER, Gan-Teng AM, Schmitz 
PI, Hendriks WD, et al. Mucositis reduction by selective elimination 
of oral flora in irradiated cancers of the head and neck: a placebo-
controlled double-blind randomized study. Int J Radiat Oncol Biol 
Phys. 2001;50:343-52. 
11. Dodd MJ, Larson PJ, Dibble SL, Miaskowski C, Greenspan D, 
MacPhail L, et al. Randomized clinical trial of chlorhexidine versus 
placebo for prevention of oral mucositis in patients receiving chemo-
therapy. Oncol Nurs Forum. 1996;23:921-7. 
12. Ferretti GA, Raybould TP, Brown AT, Macdonald JS, Greenwood 
M, Maruyama Y, et al. Chlorhexidine prophylaxis for chemotherapy- 
and radiotherapy-induced stomatitis: a randomized double-blind 
trial. Oral Surg Oral Med Oral Pathol. 1990;69:331-8. 
13. Foote RL, Loprinzi CL, Frank AR, O’Fallon JR, Gulavita S, 
Tewfik HH, et al. Randomized trial of a chlorhexidine mouth-
wash for alleviation of radiation-induced mucositis. J Clin Oncol. 
1994;12:2630-3. 
14. Pitten FA, Kiefer T, Buth C, Doelken G, Kramer A. Do cancer 
patients with chemotherapy-induced leukopenia benefit from an an-
tiseptic chlorhexidine-based oral rinse? A double-blind, block-rand-
omized, controlled study. J Hosp Infect. 2003;53:283-91. 
15. Spijkervet FK, Van Saene HK, Panders AK, Vermey A, Van Saene 
JJ, Mehta DM, et al. Effect of chlorhexidine rinsing on the oropha-
ryngeal ecology in patients with head and neck cancer who have irra-
diation mucositis. Oral Surg Oral Med Oral Pathol. 1989;67:154-61. 
16. Herrera D, Roldán S, Santacruz I, Santos S, Masdevall M, Sanz 
M. Differences in antimicrobial activity of four commercial 0.12% 
chlorhexidine mouthrinse formulations: an in vitro contact test and 
salivary bacterial counts study. J Clin Periodontol. 2003;30:307-14. 
17. Cheng KK, Chang AM. Palliation of oral mucositis symptoms in 
pediatric patients treated with cancer chemotherapy. Cancer Nurs. 
2003;26:476-84. 
18. Dodd MJ, Dibble SL, Miaskowski C, MacPhail L, Greenspan 
D, Paul SM, et al. Randomized clinical trial of the effectiveness 
of 3 commonly used mouthwashes to treat chemotherapy-induced 
mucositis. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 
2000;90:39-47. 
19. Spijkervet FK, Van Saene HK, Van Saene JJ, Panders AK, Ver-
mey A, Mehta DM. Mucositis prevention by selective elimination of 
oral flora in irradiated head and neck cancer patients. J Oral Pathol 
Med. 1990;19:486-9. 
20. Epstein JB, Vickars L, Spinelli J, Reece D. Efficacy of chlo-
rhexidine and nystatin rinses in prevention of oral complications in 
leukemia and bone marrow transplantation. Oral Surg Oral Med Oral 
Pathol. 1992;73:682-9. 
Acknowledgements
The authors want to thanks the personnel working at the Oncological 
Radiotherapy Service “Hospital 12 de Octubre” (Madrid, Spain). 
